🚀 VC round data is live in beta, check it out!
SCYNEXIS Valuation Multiples
Discover revenue and EBITDA valuation multiples for SCYNEXIS and similar public comparables like RenovoRx, Actuate Therapeutics, Corline Biomedical, Werewolf Therapeutics and more.
SCYNEXIS Overview
About SCYNEXIS
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Founded
1999
HQ
Employees
28
Website
Sectors
Financials (LTM)
EV
$6M
SCYNEXIS Financials
SCYNEXIS reported last 12-month revenue of $15M.
In the same LTM period, SCYNEXIS generated $15M in gross profit and had net loss of ($13M).
Revenue (LTM)
SCYNEXIS P&L
In the most recent fiscal year, SCYNEXIS reported revenue of $21M and EBITDA of ($8M).
SCYNEXIS expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | $21M | XXX | XXX | XXX |
| Gross Profit | $15M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (41%) | XXX | XXX | XXX |
| EBIT Margin | (125%) | XXX | (78%) | XXX | XXX | XXX |
| Net Profit | ($13M) | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | (86%) | XXX | (42%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SCYNEXIS Stock Performance
SCYNEXIS has current market cap of $44M, and enterprise value of $6M.
Market Cap Evolution
SCYNEXIS's stock price is $0.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6M | $44M | -0.3% | XXX | XXX | XXX | $-0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSCYNEXIS Valuation Multiples
SCYNEXIS trades at 0.4x EV/Revenue multiple, and (0.8x) EV/EBITDA.
EV / Revenue (LTM)
SCYNEXIS Financial Valuation Multiples
As of April 11, 2026, SCYNEXIS has market cap of $44M and EV of $6M.
Equity research analysts estimate SCYNEXIS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SCYNEXIS has a P/E ratio of (3.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $44M | XXX | $44M | XXX | XXX | XXX |
| EV (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.8x) | XXX | XXX | XXX |
| EV/EBIT | (0.3x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.4x | XXX | — | XXX | XXX | XXX |
| P/E | (3.4x) | XXX | (5.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SCYNEXIS Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SCYNEXIS Margins & Growth Rates
SCYNEXIS's revenue in the last 12 month declined by (83%).
SCYNEXIS's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.3M for the same period.
SCYNEXIS Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (83%) | XXX | (94%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (41%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (58%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 136% | XXX | 108% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 178% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SCYNEXIS Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| RenovoRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Corline Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Werewolf Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Telomir Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SCYNEXIS M&A Activity
SCYNEXIS acquired XXX companies to date.
Last acquisition by SCYNEXIS was on XXXXXXXX, XXXXX. SCYNEXIS acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SCYNEXIS
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSCYNEXIS Investment Activity
SCYNEXIS invested in XXX companies to date.
SCYNEXIS made its latest investment on XXXXXXXX, XXXXX. SCYNEXIS invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SCYNEXIS
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SCYNEXIS
| When was SCYNEXIS founded? | SCYNEXIS was founded in 1999. |
| Where is SCYNEXIS headquartered? | SCYNEXIS is headquartered in United States. |
| How many employees does SCYNEXIS have? | As of today, SCYNEXIS has over 28 employees. |
| Who is the CEO of SCYNEXIS? | SCYNEXIS's CEO is David Angulo. |
| Is SCYNEXIS publicly listed? | Yes, SCYNEXIS is a public company listed on Nasdaq. |
| What is the stock symbol of SCYNEXIS? | SCYNEXIS trades under SCYX ticker. |
| When did SCYNEXIS go public? | SCYNEXIS went public in 2014. |
| Who are competitors of SCYNEXIS? | SCYNEXIS main competitors are RenovoRx, Actuate Therapeutics, Corline Biomedical, Werewolf Therapeutics. |
| What is the current market cap of SCYNEXIS? | SCYNEXIS's current market cap is $44M. |
| What is the current revenue of SCYNEXIS? | SCYNEXIS's last 12 months revenue is $15M. |
| What is the current revenue growth of SCYNEXIS? | SCYNEXIS revenue growth (NTM/LTM) is (83%). |
| What is the current EV/Revenue multiple of SCYNEXIS? | Current revenue multiple of SCYNEXIS is 0.4x. |
| Is SCYNEXIS profitable? | No, SCYNEXIS is not profitable. |
| What is the current net income of SCYNEXIS? | SCYNEXIS's last 12 months net income is ($13M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.